US 8,629,302

Application 13/496,340 · Granted Jan 14, 2014

Methods for preparing hypericin

Estimated expiration

September 15, 2030

3y 299d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Sep 15, 2010
+ 20 years
Sep 15, 2030
PTA +0d
Sep 15, 2030
No TD
—
Final
Sep 15, 2030

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
June 4, 2012
Earliest effective filing
September 15, 2010
Issue date
January 14, 2014
PTA
0 days
Base expiry (before PTA)
September 15, 2030

September 15, 2010 + 20 years = September 15, 2030

  • National stage entry of application PCTUS2010048937, filed Sep 15, 2010
  • PRO61/242,492 — Provisional — not used for base term
  • PRO61/242,492 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 13/496,340 · US 8,629,302

PatentReply compiles the prosecution history behind US 8,629,302: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US8629302

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.